April 17, 2024 8:06am

Most sector equities are actionable, while a few need a couple more sessions to begin some gain

The time to buy is when there's blood in the streets." <Baron Rothschild>

Pre-open Indicators: 4 Positive; the risk is mine but a start

“Venimus nos emit et vendidit nos rursus” – “We have bought and sold again". That's why today's a good beginning day to start owning cell and gene therapy equities.

Never leave an investor uninformed!

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

Framing the main takeaway … pricing, volume and volatility; it also includes what happened or will happen beyond the headline which shapes today’s potential sector response as seen by RMi.

 

Wednesday: The pre-open Dow futures are UP +0.30% or (+115 points), the S&P futures are UP +0.39% or (+20 points) as the Nasdaq futures are UP +0.26% or (+46 points)

U.S. stock futures were higher on Wednesday,

European markets were higher 

Asia-Pacific markets were mixed.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Tuesday: The Dow closed UP +63.86 points or +0.17%, the S&P closed DOWN -10.41 points or -0.21% while the Nasdaq closed DOWN -19.77 points or -0.12%

Economic Data Docket: MBA Mortgage Applications, week ending April 12 (+0.1% previously)

 

Tuesday night’s RegMed Investors (RMi) Closing Bell: “declining threads extend. Elevated risk and rising tensions in the Middle East follows Iran's weekend attacks on Israel.” … https://www.regmedinvestors.com/articles/13420

 

Q2/24:  April - 10 negative and 2 positive closes

Q1/24:

  • March – 8 positive and 12 negative closes
  • February – 1 market holiday, 11 positive and 9 negative closes
  • January: 2 holidays, 11 negative and 8 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Positive Indications:

Monday, Friday, Thursday, Wednesday, Tuesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Maintaining, Ultragenyx Pharmaceuticals (RARE) closed down -$0.56 after Monday’s -$4.13, Friday’s -$3.70, Thursday’s -$0.91 and last Wednesday’s +$1.05 with a negative -$0.08or -0.19% pre-open indication.

Generation Bio (GBIO) closed down -$0.57 with a neutral pre-open indication.

Alnylam Pharmaceuticals (ALNY) closed down -$0.98 after Monday’s -$0.80, Friday’s -$3.59, Thursday’s -$0.32 and last Wednesday’s -$3.49 with a neutral pre-open indication.

Vericel (VCEL) closed down -$1.18 after Monday’s -$0.82, Friday’s -$0.82 after Thursday’s -$0.46 and last Wednesday’s -$1.16 with a neutral pre-open indication.

 

The BOTTOM LINE: From the title, Baron Rothschild, a British banker and politician from the wealthy international Rothschild family, once said that the best time to buy is “when there is blood in the streets.”

In simple words, when everyone else is selling, it's a great time to purchase. However, this advice is far easier said than done.

It’s STILL all about demand, there is a 5-session supply of oversold.

Reiterating …

  • An escalating Iran-Israel conflict will soon trigger a far-larger fear spike and a retreat from equities; however, the cell and gene therapy sector is bottoming…
  • Stocks will continue under pressure.

The Bumps in Tuesday’s sessions reflect on Wednesday:

  • Major indexes remain clearly below their 50-day moving averages.
  • The small-cap Russell 2000 fell 0.4%, hitting a fresh two-month low
  • The 10-year Treasury yield rose 3 basis points to 4.66%, nearly hitting 4.7% intraday.

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • Never forget, one of my usual lines. “The sector is … still what it is, until it isn’t and even then, it doesn’t seem to be … that is after taking a deep breath and holding it.”
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.